Journal Information
Vol. 36. Issue 9.
Pages 525-532 (October 2000)
Vol. 36. Issue 9.
Pages 525-532 (October 2000)
Full text access
Diagnóstico y tratamiento de la exacerbación infecciosa en la fibrosis quística
Visits
24277
A. Escribano Montaner*
Unidad de Neumología Infantil. Servicio de Pediatría. Hospital Clínico Universitario de Valencia. Departamento POG. Universidad de Valencia.
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
J.M. Rommens, M.C. Iannuzzi, B. Kerem, M.L. Drumm, G. Melber, M. Dean, et al.
Identification of cystic fibrosis gene: chromosome walking and jumping.
Science, 245 (1989), pp. 1059-1065
[2.]
J.D. Acton, J.M. Stark.
Management of acute exacerbations of cystic fibrosis lung disease.
Clin Pulm Med, 6 (1999), pp. 153-164
[3.]
B.C. Marsall.
Pathophysiology of pulmonary disease in cystic fibrosis.
Semin Respir Crit Care Med, 15 (1994), pp. 364-374
[4.]
B.W. Ramsey.
Management of pulmonary disease in patients with cystic fibrosis.
N Engl J Med, 335 (1996), pp. 179-188
[5.]
B.C. Marshall, W. Samuelson.
Basic therapies in cystic fibrosis Does standard therapy work?..
Clin Chest Med, 19 (1998), pp. 487-504
[6.]
P.B. Davis, M. Drumm, M.W. Konstan.
Cystic fibrosis.
Am J Respir Crit Care Med, 154 (1996), pp. 1229-1256
[7.]
Practical guidelines for cystic fibrosis care,
[8.]
J.D. Eisemberg.
Antibiotic use in cystic fibrosis.
Curr Opin Pulm Med, 2 (1996), pp. 439-446
[9.]
Grupo de trabajo “Fibrosis Quística” (Sociedad Española de Neumología, Pediátrica)..
Protocolo de diagnóstico y seguimiento de. los enfermos con fibrosis quística.
An Exp Pediatr, 50 (1999), pp. 625-634
[10.]
Clinical P ractice Guidelines for Cystic Fibrosis.
Treatment of pulmonary exacerbation of cystic fibrosis., CF Founation, (1997), pp. 27-29
[11.]
M.A. Donati, G. Guenette, H. Auervach.
Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary. disease.
J Pediatr, 111 (1987), pp. 28-33
[12.]
J.M. Wolter, S.D. Bowler, P.J. Nolan, J.G. McCormack.
Home intravenous therapy in cystic fibrosis: a prospective randomized trial examing clinical, quality of life, and cost aspects.
Eur Respir J, 10 (1997), pp. 896-900
[13.]
D.J. Bosworth, D.W. Nielson.
Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis.
Pediatr Pulmonol, 24 (1997), pp. 42-47
[14.]
R. Gold, S. Carpenter, H. Heurter, M. Corey, H. Levinson.
Randomized trial of ceftazidime versus placebo in the management of acute exacerbations in patients with cystic fibrosis.
J Pediatr, 111 (1987), pp. 907-913
[15.]
R.E. Wood.
What is a “pulmonary exacerbation” in cystic fibrosis?.
J Pediatr, 111 (1987), pp. 841-842
[16.]
W.E. Regelmann, G.R. Elliott, W.J. Warwick, C.C. Clawson.
Reduction of sputum Pseudomonas aeruginosa density by antibiotics. improves lung function in cystic fibrosis more than do bronchodilators and chest phisiotherapy alone.
Am Rev Respir Dis, 141 (1990), pp. 914-921
[17.]
S.V. Turpin, M.R. Knowles.
Treatment of pulmonary disease in patients with cyscic fibrosis..
pp. 277-344
[18.]
B.W. Ramsey, K.R. Wentz, A.L. Smith, M. Richardson, P. Williams-Warren, D.L. Hedges, et al.
Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.
Am Rev Respir Dis, 144 (1991), pp. 331-337
[19.]
L. Saiman, W. Niu, A. Prince, H. Neu.
A referral center to study multiresistant Pseudomonas aeruginosa.
Pediatr Pulmonol, (1991), pp. 279
[20.]
F.J. McLaughlin, W.J. Matthews Jr., D.J. Strieder, B. Sullivan, A. Taneja, P. Murphy, et al.
Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin and azlocillin-placebo.
J Infect Dis, 147 (1983), pp. 559-567
[21.]
R. Gold, A. Overmeyer, B. Knie, P.C. Fleming, H. Levison.
Controlled trial of ceftazidime versus ticarcillin and tobramycin in the. treatment of acute respiratory exacerbations in patients with cystic fibrosis.
Pediatr Infect Dis, 4 (1985), pp. 172-177
[22.]
M.A. Jackson, H. Kusmiesz, S. Shelton, C. Prestidge, R.I. Kramer, J.D. Nelson.
Comparison of piperacillin vs Ticarcillin Plus tobramycin in the treatment of acute respiratory exacerbations of cystic fibrosis..
Pediatr Infect Dis, 5 (1986), pp. 440-443
[23.]
J.L. Burns.
Treatment of cepacia: in search of the magic bullet [resumen].
Pediatr Pulmonol, (1997), pp. 90
[24.]
T. Jensen, S.S. Pedersen, N. Hoybi, C. Koch.
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
Eur J Clin Microbiol, 6 (1987), pp. 618-622
[25.]
E. Rey, J.M. Treluyer, G. Pons.
Drug disposition in cystic fibrosis.
Clin Pharmacokinet, 35 (1998), pp. 313-329
[26.]
D.J. Touw.
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
Pharm World Sci, 20 (1998), pp. 149-160
[27.]
P.M. Mendelman, A.L. Smith, J. Levy, A. Weber, B.R. Ramsey, R. Davis.
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis.
Am Rev Respir Dis, 132 (1985), pp. 761-765
[28.]
R.C. Stern.
Inpatients treatment of cystic fibrosis pulmonary disease..
Treatment of the hospitalized cystic fibrosis patient., pp. 79-133
[29.]
P.J. Wood, L.L. Ioannides-Demos, S.C. Li, T.J. Williams, B. Hitkey, W.J. Spicer, et al.
Minimisation of aminoglycoside toxicity inpatients. with cystic fibrosis.
Thorax, 51 (1996), pp. 369-373
[30.]
R.D. Bates, M.C. Ionannides, W.J. Jones, K. McCoy, G. Young, A. Cox, et al.
Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis..
Chest, 112 (1997), pp. 1208-1213
[31.]
P. Vic, S. Ategbo, D. Turk, M.O. Husson, V. Launay, G.A. Loeuille, et al.
Efficacy, tolerance, and pharmacokinetics of once daily tobramicyn for pseudomonas exacerbations in cystic fibrosis.
Arch Dis Child, 78 (1998), pp. 536-539
[32.]
S.P. Conway, M.N. Pond, A. Watson, C. Etherington, H.L. Robey, M.H. Goldman.
Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.
Thorax, 52 (1997), pp. 987-993
[33.]
M.J. Ledson, M.J. Gallager, C. Cowperthwaite, R.P. Convery, M.J. Walsahaw.
Four years’ experience of intravenous colomycin in an. adult cystic fibrosis unit.
Eur Respir J, 12 (1998), pp. 592-594
[34.]
S.M. Rosenberg, C.M. Schramm.
Predictive value of pulmonary function testing during pulmonary exacerbations in cystic fibrosis.
Pediatr Pulmonol, 16 (1993), pp. 227-235
[35.]
P. Cahen, M. Le Bourgeois, C. Delacourt, C. Custère, P. Nicaise, J. De Blic, et al.
Serum bactericidal test as a prognostic indicator in. acute pulmonary exacerbations of cystic fibrosis.
Pediatrics, 91 (1993), pp. 451-455
[36.]
G.B. Winnie, R.G. Cowan, N.A. Wade.
Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis.
J Pediatr., 114 (1989), pp. 309-314
[37.]
J.E. Van Wye, M.S. Collins, M. Baylor, J.E. Pennington, Y.P. Hsu, V. Sampanvejsopa, et al.
Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis.
Pediatr Pulmonol, 9 (1990), pp. 7-18
[38.]
C. Braggion, L.M. Cappelletti, M. Cornacchia, L. Zanolla, G. Mastella.
Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over randomized study.
Pediatr Pulmonol, 19 (1995), pp. 16-22
[39.]
R. Arens, D. Gozal, K.J. Omlin, J. Vega, K.P. Boyd, T.G. Keens, et al.
Comparison of high frequency chest compression and convencional chest physiotherapy in hospitalized patients with cystic fibrosis..
Am J Respir Crit Care Med, 150 (1994), pp. 1154-1157
[40.]
J. Thomas, D.J. Cook, D. Brooks.
Chest physical therapy management of patients with cystic fibrosis. A meta-analysis.
Am J Respir Crit Care Med, 151 (1995), pp. 846-850
[41.]
G.J. Gropp.
Effectiveness of bronchodilators in cystic fibrosis (resumen).
Am J Med, 100 (1996), pp. 19S-29S
[42.]
R.W. Wilmott, R.S. Amin, A.A. Colin, A. Devault, A.J. Dozor, H. Eigen, et al.
Aerolized recombinant human dnase in hospitalized cystic. fibrosis patients with acute pulmonary exacerbations.
Am J Respir Crit Care Med, 153 (1996), pp. 1914-1917
[43.]
M.A. Thomson, P. Quirk, C.E. Swanson, B.J. Thomas, T.L. Holt, P.J. Francis, et al.
Nutricional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction.
Nutrition, 11 (1995), pp. 350-354
[44.]
B.W. Ramsey, P.M. Farrell, P. Pencharz.
Nutricional assessment and management in cystic fibrosis: a consensus report The Consensus Committee..
Am J Clin Nutr, 55 (1992), pp. 108-116
[45.]
R.W. Shepherd, T.I. Holt, G. Cleghorn, L.C. Ward, P. Francis.
Short term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover.
Am J Clin Nutr, 48 (1988), pp. 235-239
[46.]
E.D. Allen, A.B. Mick, J. Nicol, K.S. McCoy.
Prolonged parenteral nutrition for cystic fibrosis patients.
Nut Clin Pract, 109 (1995), pp. 73-79
[47.]
J.D. Hosenpud, L.E. Bennett, B.M. Keck, B. Fiol, R.J. Novick.
The Registry of the International Society for Heart and lung Transplantation: Fourteen official report-1997.
J Heart Lung Transplant, 16 (1997), pp. 691-712
[48.]
G. Massard, H. Shennib, D. Metras, J. Camboulives, L. Viard, D.S. Mulder, et al.
Double lung transplantation in mechanically ventilated patients with cystic fibrosis..
Ann Thorac Surg, 55 (1993), pp. 1087-1091
[49.]
P.A. Flume, T.M. Egan, J.H. Westeman, L.I. Paradowski, J.R. Yankaskas, F.C. Detterberck, et al.
Lung transplantation for mechanically. ventilated patients..
J Heart Lung Transplant, 13 (1994), pp. 15-21
[50.]
J.S. Garland, Y.M. Chan, K.J. Kelly, T.B. Rice.
Outcome of infants with cystic fibrosis requiring mechanical ventilation for respiratory failure.
Chest, 96 (1989), pp. 136-138
[51.]
A.J. Piper, S. Parker, P.J. Torzillo, C.E. Sullivan, P.T.P. Bye.
Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure.
Chest, 102 (1992), pp. 846-850
[52.]
M.E. Hodson, B.P. Madden, M.H. Steven, V.T. Tsang, M.H. Yacoub.
Non-invasive mechanical ventilation for cystic fibrosis patients– apotential bridge to transplantation.
Eur Respir J, 4 (1991), pp. 524-527
[53.]
M.W. Elliot, A.K. Simonds, M.P. Carroll, J.A. Wedzicha, M.A. Branthwaite.
Domiciliary nocturnal nasal intermitent positive pressure ventilation in hypercapnic respiratory failure due to chronic obstructive lung disease: effects of sleep and quality of life.
Thorax, 47 (1992), pp. 342-348
[54.]
J.H. Conway, R.A. Hitchcock, R.C. Godfrey, M.P. Carroll.
Nasal intermitent positive pressure ventilation in acute exacerbations of chronic obstructive pulmonary disease– a preliminary study.
Respir Med, 87 (1993), pp. 387-394
[55.]
M.C. Martínez Carrasco, S. Domínguez García Cano, M.T. García-Marcos, M.I. Barrios Gómez de Agüero, M.C. Antelo Landeira.
Ventilación nasal con presión positiva continua o intermitente en pacientes con fibrosis quística y fracaso respiratorio hipercápnico.
An Esp Pediatr, (1999), pp. 79-80
Copyright © 2000. Sociedad Española de Neumología y Cirugía Torácica